Stock Analysis on Net
Stock Analysis on Net

Medtronic PLC (NYSE:MDT)

$24.99

Economic Value Added (EVA)

Microsoft Excel

EVA is registered trademark of Stern Stewart.

Economic value added or economic profit is the difference between revenues and costs,where costs include not only expenses, but also cost of capital.

Paying user area


We accept:

Visa Mastercard Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check

Economic Profit

Medtronic PLC, economic profit calculation

US$ in millions

Microsoft Excel
12 months ended: Apr 24, 2026 Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2026 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


The organization has consistently reported negative economic profit throughout the observed period, signifying that the returns generated from operations have not exceeded the cost of the capital employed. Despite this persistent deficit, a discernible trend toward improved economic value creation is evident, as the gap between operating profits and the capital charge has narrowed over the six-year span.

Net Operating Profit After Taxes (NOPAT)
NOPAT exhibited significant volatility, peaking at 4,888 million in 2022 before experiencing a decline to a period low of 3,736 million in 2024. A strong recovery followed in the final two years, with figures rising to 4,980 million in 2025 and reaching 5,540 million by 2026, indicating a marked improvement in operational profitability.
Capital Structure and Cost of Capital
Invested capital remained relatively stable, fluctuating within a narrow range between 68,670 million and 72,405 million. Simultaneously, the cost of capital demonstrated a gradual downward trajectory, decreasing from 12.33% in 2021 to 11.77% by 2026, which marginally lowered the threshold required for the company to achieve a positive economic profit.
Economic Profit Performance
Economic profit remained negative across all reported years, with the deepest deficit occurring in 2021 at -4,876 million. Since 2024, a consistent trend of recovery is observed, as the economic profit improved to -2,824 million by 2026. This improvement is primarily attributed to the growth in NOPAT, which began to offset the capital charges more effectively toward the end of the period.

Net Operating Profit after Taxes (NOPAT)

Medtronic PLC, NOPAT calculation

US$ in millions

Microsoft Excel
12 months ended: Apr 24, 2026 Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021
Net income attributable to Medtronic
Deferred income tax expense (benefit)1
Increase (decrease) in allowances and credit losses2
Increase (decrease) in deferred revenue3
Increase (decrease) in restructuring reserve4
Increase (decrease) in equity equivalents5
Interest expense, net
Interest expense, operating lease liability6
Adjusted interest expense, net
Tax benefit of interest expense, net7
Adjusted interest expense, net, after taxes8
(Gain) loss on marketable securities
Investment income, before taxes
Tax expense (benefit) of investment income9
Investment income, after taxes10
Net income (loss) attributable to noncontrolling interest
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in allowances and credit losses.

3 Addition of increase (decrease) in deferred revenue.

4 Addition of increase (decrease) in restructuring reserve.

5 Addition of increase (decrease) in equity equivalents to net income attributable to Medtronic.

6 2026 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

7 2026 Calculation
Tax benefit of interest expense, net = Adjusted interest expense, net × Statutory income tax rate
= × 21.00% =

8 Addition of after taxes interest expense to net income attributable to Medtronic.

9 2026 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =

10 Elimination of after taxes investment income.


The analysis of operational profitability and net earnings reveals a cyclical trajectory characterized by a peak in 2022, a subsequent contraction reaching a trough in 2024, and a strong recovery phase through 2026.

Net Operating Profit After Taxes (NOPAT) Trends
NOPAT exhibits significant volatility over the observed period. An initial increase is noted from US$ 4,049 million in 2021 to US$ 4,888 million in 2022, followed by a two-year decline that brings the value down to US$ 3,736 million by 2024. A robust recovery is observed thereafter, with NOPAT ascending to US$ 4,980 million in 2025 and reaching a period high of US$ 5,540 million in 2026. This upward movement in the final two years indicates an expansion in core operational efficiency.
Net Income Performance
Net income attributable to the entity mirrors the general trajectory of NOPAT but demonstrates different magnitudes of change. A sharp increase occurred in 2022, reaching US$ 5,039 million, which was followed by a contraction to US$ 3,758 million in 2023 and a further slight decrease to US$ 3,676 million in 2024. The recovery phase aligns with NOPAT, with net income climbing to US$ 4,801 million by 2026.
Relationship Between Operational Profit and Net Earnings
A comparison between NOPAT and net income reveals that operational profitability generally exceeds the final net income, which is typical given that NOPAT excludes the impact of financing costs. A notable anomaly is observed in 2022, where net income (US$ 5,039 million) surpassed NOPAT (US$ 4,888 million), suggesting the influence of non-operating income or one-time gains. In the subsequent years, the gap widens significantly; by 2026, NOPAT exceeds net income by US$ 739 million, reflecting a strengthening of the core operating engine relative to the final bottom line.

Cash Operating Taxes

Medtronic PLC, cash operating taxes calculation

US$ in millions

Microsoft Excel
12 months ended: Apr 24, 2026 Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021
Income tax provision (benefit)
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense, net
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).


The analysis of tax metrics from April 2021 to April 2026 reveals a period of volatility characterized by a consistent divergence between accounting tax provisions and actual cash tax outflows.

Cash Operating Taxes Trend
Cash operating taxes exhibited a strong upward trajectory between 2021 and 2023, rising from 925 million US$ to a peak of 1,979 million US$. Following this peak, expenditures experienced a moderate decline, eventually stabilizing near 1,428 million US$ in the 2025 and 2026 periods.
Income Tax Provision Volatility
The income tax provision demonstrated more pronounced fluctuations than the cash tax outflows. After an initial increase from 265 million US$ in 2021 to 455 million US$ in 2022, a sharp spike occurred in 2023, reaching 1,580 million US$. This was followed by a downward trend to 936 million US$ by 2025, before rebounding to 1,299 million US$ in 2026.
Comparison of Cash Taxes versus Provisions
A persistent discrepancy is observed where cash operating taxes exceed the income tax provision in every reporting period. This indicates that the actual cash outflows for taxes are consistently higher than the tax expenses recognized for accounting purposes. While the variance was substantial in the early periods—reaching 731 million US$ in 2022—the gap narrowed significantly by 2026, reducing to 129 million US$.

Invested Capital

Medtronic PLC, invested capital calculation (financing approach)

US$ in millions

Microsoft Excel
Apr 24, 2026 Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021
Current debt obligations
Long-term debt
Operating lease liability1
Total reported debt & leases
Shareholders’ equity
Net deferred tax (assets) liabilities2
Allowances and credit losses3
Deferred revenue4
Restructuring reserve5
Equity equivalents6
Accumulated other comprehensive (income) loss, net of tax7
Noncontrolling interests
Adjusted shareholders’ equity
Construction in progress8
Available-for-sale debt securities9
Invested capital

Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of allowance for doubtful accounts receivable.

4 Addition of deferred revenue.

5 Addition of restructuring reserve.

6 Addition of equity equivalents to shareholders’ equity.

7 Removal of accumulated other comprehensive income.

8 Subtraction of construction in progress.

9 Subtraction of available-for-sale debt securities.


The analysis of invested capital from 2021 to 2026 reveals a period of relative stability, with total invested capital fluctuating within a narrow range between approximately $68.6 billion and $72.4 billion. While the total capital base remained consistent, there were notable shifts in the underlying composition of debt and equity.

Invested Capital Volatility
Invested capital experienced a slight downward trajectory from $72,405 million in 2021 to a trough of $68,670 million in 2024. This was followed by a recovery phase, with values increasing to $70,365 million in 2025 and $71,088 million in 2026. This pattern suggests a disciplined management of the capital base, avoiding aggressive expansion or significant contraction.
Debt and Lease Obligations
Total reported debt and leases exhibited a non-linear trend. Following a decrease from $27,404 million in 2021 to $24,984 million in 2022, debt levels climbed steadily, peaking at $29,626 million in 2025. A marginal reduction to $29,148 million was observed in 2026, indicating a period of increased leverage toward the end of the analyzed timeframe.
Shareholders' Equity Trends
Shareholders' equity showed an inverse relationship with debt levels during several periods. After reaching a peak of $52,551 million in 2022, equity underwent a consistent decline over the next three years, reaching a low of $48,024 million in 2025. A reversal of this trend occurred in 2026, with equity rising back to $49,463 million.

The interaction between the financing components indicates that the increase in debt and leases, particularly between 2023 and 2025, served as a primary offset to the decline in shareholders' equity. This strategic balancing acted to stabilize the total invested capital, ensuring that the operational resource base remained steady despite the shift in the capital structure toward higher leverage.


Cost of Capital

Medtronic PLC, cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2026-04-24).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2025-04-25).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2024-04-26).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2023-04-28).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2022-04-29).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2021-04-30).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

Medtronic PLC, economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Apr 24, 2026 Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021
Selected Financial Data (US$ in millions)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).

1 Economic profit. See details »

2 Invested capital. See details »

3 2026 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


The analysis of the economic value added metrics reveals a persistent period of negative economic profit and a negative economic spread ratio from 2021 through 2026. While value destruction is evident throughout the period, a positive trajectory is observable in the latter years, suggesting a gradual improvement in the efficiency of capital utilization relative to the cost of capital.

Economic Profit Trends
Economic profit remained negative across the entire six-year period. A significant loss was recorded in 2021 at -4,876 million USD, followed by volatility between 2022 and 2024. Starting in 2025, a consistent recovery trend emerged, with losses narrowing to -3,346 million USD in 2025 and further improving to -2,824 million USD by 2026. This indicates a reduction in the shortfall between operating returns and the required capital charge.
Invested Capital Stability
Invested capital exhibited relative stability, fluctuating within a narrow range between 68,670 million USD and 72,405 million USD. The lowest level of capital employment was observed in 2024, followed by a gradual increase through 2026. The fact that economic profit improved while invested capital also rose slightly from 2024 to 2026 suggests that recent capital allocations may be generating higher incremental returns.
Economic Spread Ratio Analysis
The economic spread ratio remained negative throughout the observed timeframe, confirming that the return on invested capital consistently lagged behind the weighted average cost of capital. The ratio reached its lowest point in 2021 at -6.73% and experienced a secondary dip in 2024 at -6.55%. However, a notable recovery is observed in the final two years, with the ratio improving to -4.76% in 2025 and -3.97% in 2026. This trend indicates a narrowing gap between the cost of capital and the actual return on investment.

Economic Profit Margin

Medtronic PLC, economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Apr 24, 2026 Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021
Selected Financial Data (US$ in millions)
Economic profit1
 
Net sales
Add: Increase (decrease) in deferred revenue
Adjusted net sales
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).

1 Economic profit. See details »

2 2026 Calculation
Economic profit margin = 100 × Economic profit ÷ Adjusted net sales
= 100 × ÷ =

3 Click competitor name to see calculations.


The financial performance over the observed period is characterized by a persistent negative economic profit, though a clear trend toward recovery is evident. While the organization has consistently failed to generate returns exceeding its cost of capital, the magnitude of the economic loss has decreased significantly over the long term.

Economic Profit Trends
Economic profit remained negative throughout the period, reaching a peak deficit of -4,876 million USD in 2021. Following a period of volatility between 2022 and 2024, where losses fluctuated between -3,543 million USD and -4,498 million USD, a consistent narrowing of the deficit is observed in 2025 and 2026, with the loss reducing to -2,824 million USD by the end of the period.
Adjusted Net Sales Growth
A general increase in adjusted net sales is observed, rising from 30,182 million USD in 2021 to 36,418 million USD by 2026. Aside from a marginal contraction in 2023, the revenue stream exhibits steady expansion, which suggests a growth in market scale that coincides with the improvement in economic profit.
Economic Profit Margin Analysis
The economic profit margin reflects a gradual improvement in capital efficiency. Starting at -16.16% in 2021, the margin experienced a period of instability before entering a phase of sustained recovery. The margin improved to -9.98% in 2025 and further to -7.76% by 2026. This upward trend indicates that the organization is reducing the gap between its operational returns and its cost of capital, moving closer to a state of positive economic value creation.